

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCES United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.G. 20201 www.mispto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/819,252	03/27/2001	Scott A. Waldman	TJU-2389 2091		
7	590 02/19/2002			NIED.	
WOODCOCK	Mark DeLuca, Esq. WOODCOCK WASHBURN KURTZ			EXAMINER DAVIS, NATALIE A	

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

ART UNIT PAPER NUMBER

642

DATE MAILED: 02/19/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicant/s)					
	Application No.	Applicant(s)					
	09/819,252	WALDMAN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Natalie A. Davis	1642					
The MAILING DATE of this communication app Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) do will apply and will expire SIX (6) MONTHS from the application to become ABANDON	timely filed ays will be considered timely. m the mailing date of this communication. IED (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on 28 L	December 2001 .						
·—	is action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-33</u> is/are pending in the application.							
4a) Of the above claim(s) <u>1-24,28,32 and 33</u> is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>25-27 and 29-31</u> is/are rejected.							
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9)☐ The specification is objected to by the Examine							
10)☐ The drawing(s) filed on is/are: a)☐ acce							
Applicant may not request that any objection to th							
11) The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language pro	ovisional application has been r	eceived.					
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)					

Application/Control Number: 09/819,252

Art Unit: 1642

DETAILED ACTION

Applicant's election of Group III, claims 25-32 and Species B (PCR) in Paper No. 11 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The requirement is still deemed proper and is therefore made FINAL.

Species A will be rejoined with B and claims 25-27 and 29-31 as they read on PCR and gene transcription product are being examined as belonging to the elected Group III, while claims 1-24, 28, and 32-33 are withdrawn from examination as being drawn to a non-elected invention.

Information Disclosure Statement

The information disclosure statement has been considered. A signed copy is attached hereto.

Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 25-27 and 29-31 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
- 3. Factors to be considered in determining whether undue experimentation is required, are summarized in *Ex parte* Forman, 230 USPQ 546 (BPAI 1986). They include the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability or unpredictability of the art, the breadth of the claims, and the quantity of experimentation which would be required in order to practice the invention as claimed.

Application/Control Number: 09/819,252

Art Unit: 1642

Mallo, et al., (1997) is cited in order to establish the general state of the art and the level 4. of predictability of diagnosing stomach and esophageal cancer by detecting the presence of CDX2 in a tissue sample. Mallo, et al., disclose a decrease in CDX1 and 2 expression in human colorectal carcinogenesis and no detectable expression in other tissues including stomach (p. 37, col. 2). The specification discloses carcinoma derived from stomach or esophageal express CDX2 and its mRNA as a specific biomarker for the presence of cancer cells in tissues, and that this characteristic permits the detection of CDX2 mRNA by RT-PCR analysis as a diagnostic test to patients with cancer. However there is no evidence in the art or exemplification in the specification indicating that the detection of CDX2 is indicative of the presence of stomach or esophageal cancer. Since Mallo, et al., disclose no detectable expression of CDX2 in stomach, it would be unpredictable to diagnose stomach or esophageal cancer based on the detection of CDX2. Likewise, the specification does not guide or exemplify what levels of CDX2 detection in cancer tissue in comparison to normal tissue would be indicative of stomach or esophageal cancer. The specification only gives guidance as to which methods may be used to detect CDX2 in tissue. Accordingly, one of skill in the art would not be able to practice the claimed invention because undue experimentation would be required.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Natalie A. Davis whose telephone number is 703-308-6410. The examiner can normally be reached on M-F 8-5:30 (every other Friday off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa PhD can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4315 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Natalie Davis, PhD February 8, 2002

ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600